Ge Longhui, January 31 | Yahong Pharmaceutical (688176.SH) recently said during a survey receiving institutional investors that the international multi-center phase III clinical trial of APL-1702 to treat high-grade squamous intraepithelial lesions of the cervix has reached the main research end point and will disclose data from this clinical trial at the 2024 European Association for Research on Genital Tract Infections and Oncology (EUROGIN) conference.
The company will actively communicate with the regulatory authorities to submit a new drug marketing application for this drug. Regarding the NDA situation, the company will strictly comply with the “Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules” and other relevant regulations.
Currently, traditional surgical treatment is mainly used for patients with precancerous cervical disease. The most common treatment methods include cervical annular electroctomy (LEEP) and cold knife conical resection (CKC). There are no non-surgical treatment products on the market. In the future, APL-1702 will be priced based on various factors such as the comprehensive cost of traditional surgical treatment, the innovation and pharmacoeconomic evaluation of the product itself, and patients' ability to pay.